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Abstract
Persistent viruses are kept in check by specific lymphocytes. The clonal T cell receptor (TCR) repertoire against
Epstein-Barr virus (EBV), once established following primary infection, exhibits a robust stability over time. However,
the determinants contributing to this long-term persistence are still poorly characterized. Taking advantage of an in
vivo clinical setting where lymphocyte homeostasis was transiently perturbed, we studied EBV antigen-specific CD8
T cells before and after non-myeloablative lympho-depleting chemotherapy of melanoma patients. Despite more
advanced T cell differentiation, patients T cells showed clonal composition comparable to healthy individuals, sharing
a preference for TRBV20 and TRBV29 gene segment usage and several co-dominant public TCR clonotypes.
Moreover, our data revealed the presence of relatively few dominant EBV antigen-specific T cell clonotypes, which
mostly persisted following transient lympho-depletion (TLD) and lymphocyte recovery, likely related to absence of
EBV reactivation and de novo T cell priming in these patients. Interestingly, persisting clonotypes frequently co-
expressed memory/homing-associated genes (CD27, IL7R, EOMES, CD62L/SELL and CCR5) supporting the notion
that they are particularly important for long-lasting CD8 T cell responses. Nevertheless, the clonal composition of
EBV-specific CD8 T cells was preserved over time with the presence of the same dominant clonotypes after non-
myeloablative chemotherapy. The observed clonotype persistence demonstrates high robustness of CD8 T cell
homeostasis and reconstitution.
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Introduction
Primary Epstein-Barr virus (EBV) infection is associated with
massive viral replication. In spite of the generation of a robust T
cell specific immune response, EBV establishes a latent
infection in B cells [1]. Nevertheless, healthy EBV-infected
individuals remain asymptomatic throughout their life due to
viral containment by antigen-specific memory CD8 T
lymphocytes [1-3]. As increasing attention is devoted to
optimizing therapeutic vaccination strategies against cancer,
the immune control of chronic EBV infection represents an
interesting model system to study the mechanisms involved in
the generation and maintenance of life-long protective immune
responses.
The antigen-primed CD8 T cell pool is highly heterogeneous
and comprises T cell subpopulations at varying degrees of
cellular differentiation based on their phenotype, function and
anatomic location, thus making the distinction between
“effector” and “memory” cytolytic T cells challenging [4-6].
Generally, memory-like T cells display long-term survival and
self-renewal abilities, high proliferative potential, and the
capacity to rapidly and efficiently produce effector cells in
response to antigen re-encounter [7-9]. In contrast, effector T
cells have the capacity to migrate to the site of inflammation, to
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kill antigen-bearing target cells and secrete various cytokines
(e.g. IFNγ, TNFα) [10].
Whether memory cell responses are maintained for
prolonged periods or periodically “renewed” remains a matter
of debate. It is a particularly difficult question to address in
humans since it requires in-depth analysis of protective
immune responses over extended periods of time. In this
regard, the T cell receptor (TCR) is an excellent marker that
allows antigen-specific responses to be followed along T cell
differentiation and over time [11]. Thorough analyses of both
viral and tumor antigen-specific CD8 T cell responses have
revealed that the antigen-specific T cell repertoire is generally
composed of highly frequent (also defined as dominant) as well
as less frequent (defined as non-dominant) T cell clonotypes
[12,13]. Through a process known as TCR clonotype selection,
certain clonotypes may become more dominant along T cell
differentiation [14-16] or throughout the time course of infection
[17]. Persistence of human virus-specific T cell clonotypes over
several years has been demonstrated in humans with various
viral infections: influenza [18], herpes simplex virus [19,20],
EBV [21], cytomegalovirus (CMV) [14] and human
immunodeficiency virus (HIV) [22]. Recently, Klarenbeek and
colleagues [23] addressed the question of whether the clonal
repertoire that is established during the early phase of
infections against CMV and EBV is maintained over extended
periods of time. They found that immune responses were very
stable, and once established did not evolve during the 5-year
follow up [23]. While herpes virus-specific T cell responses
revealed an unprecedented stability of the TCR clonotype
repertoire over time following primary infection, less is known
regarding their persistence during conditions of immunological
stress in asymptomatic carriers.
In the present study, we examined the robustness of the
EBV antigen-specific responses in an in vivo setting where the
balance between virus and immune response may be
temporarily compromised following transient lympho-depletion
(TLD). Specifically, we evaluated the EBV antigen-specific CD8
T cell clonotype composition and persistence in melanoma
patients who were treated with non-myeloablative
chemotherapy regimen, followed by adoptive cell transfer
(ACT) of autologous peripheral blood mononuclear cells
(PBMCs) [24,25]. To quantitatively assess virus-specific T cell
responses, direct ex vivo clonotypic analyses combined to
gene expression profiling of individual antigen-specific T cells
were performed [13]. The anti-viral T cell responses in patients
were more differentiated compared with healthy individuals,
comprising both memory and effector CD8 T cells. Dominant
TCR beta-chain clonotypes, including several public TCR
sequences, were found to persist with time in healthy
individuals and following TLD and ACT among patients. We
then studied T cell clonotypes with fluctuating frequencies
following TLD and immune reconstitution, and observed that
clonotypes with increased frequency carried a polyfunctional
memory/homing gene expression profile (CD27, IL7R, EOMES,
CD62L/SELL and CCR5). Altogether, our data suggest that the
EBV-specific T cell repertoire persists not only under steady-
state conditions but also during transient immunological
perturbations.
Materials and Methods
Ethics statement
The clinical studies were designed and conducted according
to the relevant regulatory standards, and approved by (i) the
ethical commission of the University of Lausanne, (ii) the LICR
Protocol Review Committee, and (iii) the Swiss national
regulatory authority (Swissmedic). They have been registered
in the NCI clinical trials under the number NCT00324623 and
EU20607 (www.clinicaltrials.gov). All blood samples from
patients were collected upon written informed consent.
Peripheral blood samples from four EBV-positive healthy
donors BCL3, BCL4, BCL7 and BCL8, aged between 25 and
45 years, were collected at two time-points, in the years 2002
and 2006, and all donors gave written informed consent.
Melanoma patients and treatment
Blood samples from five EBV-positive melanoma patients,
aged between 39 to 75 years, enrolled in phase I clinical trials
at the Department of Oncology of the Lausanne University
Hospital (Switzerland), were taken at various time-points before
and after treatment. After collection of PBMCs by
leukapheresis (Leuka), patients received non-myeloablative
chemotherapy regimen consisting of either busulfan at 2 mg/kg
(patients LAU 618 and LAU 672) or cyclophosphamide (CTX)
at 30 mg/kg (LAU 1144 and first round for LAU 1013) or 60
mg/kg (LAU 936 and second round for LAU 1013) for two days
and fludarabine at 30 mg/m2 for 3 days [24,25]. Three days
after the last injection of fludarabine, autologous PBMCs were
reinfused and peptide vaccination with the Melan-A analog
peptide emulsified in incomplete Freunds’ adjuvant was given
subcutaneously as previously described [24]. Patient LAU 1144
also received a soluble LAG-3 protein as adjuvant.
Antibody levels against EBV in melanoma patients
Plasma samples were taken from all patients at several time-
points before and after lympho-depleting treatment and
analyzed for alterations in antibody levels known to be
associated with a state of EBV reactivation. Specifically, we
compared the plasma antibody levels against three EBV
expressed proteins: EBNA-IgG (Epstein-Barr Nuclear Antigen),
EA-IgG (Early Antigen), VCA-IgG and IgM (Viral Capsid
Antigen). EBV-specific antibodies were assayed using the
AtheNA Multi-Lyte EBV test system (Zeus scientific,
Sommerville, NJ, USA) on a Luminex 200 reader according to
the manufacturer instructions. Results were expressed as
arbitrary units.
Cell preparation and flow cytometry
PBMCs were obtained by density centrifugation using Ficoll-
Hypaque (Pharmacia, Uppsala, Sweden). CD8 T lymphocytes
were positively enriched from cryopreserved PBMCs using
anti-CD8-coated magnetic microbeads (Miltenyi Biotech,
Bergish Gladbach, Germany). PE-labeled HLA-A*0201/peptide
multimers were prepared as described previously [26] with the
HLA-A2 restricted epitope GLCTLVAML (referred as A2/GLC)
derived from the EBV lytic protein BMFL1. Cells were first
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stained with PE-labeled multimers for 1hr at room temperature
(RT) in PBS, 0.2% BSA, 50 uM EDTA, and then with
appropriate antibodies (20 min at 4°C). Cells were either
directly analyzed (LSR-II flow cytometer; BD Biosciences, San
Diego, CA) or sorted into defined populations using a
FACSVantage SE machine (BD Biosciences). The following
monoclonal Abs were purchased from BD Biosciences or BD
PharMingen; anti-CD28-FITC, anti-CD8-allophycocyanin/Cy7,
anti-CCR7 rat IgG mAB, goat anti-rat IgG-allophycocyanin, and
CD3-AmCyan-A. Anti-CD45RA-PE-Texas Red mAb was
purchased from Beckman Coulter (Marseille, France).
Generation of T cell clones and culture
HLA-A2/multimer+ CD8+ T cell subsets were defined as
effector-memory (EM) CCR7-CD45RA-CD28+ (EM28pos), CCR7-
CD45RA-CD28- (EM28neg) and effector CCR7-CD45RA+CD28-
(EMRA), and were sorted by flow cytometry directly ex vivo
(Figure S1). Sorted cells were cloned by limiting dilution and
expanded in RPMI 1640 medium supplemented with 8%
human serum (HS), 150 U/ml recombinant human IL-2 (rhIL-2;
a gift from GlaxoSmithKline), 1 microgram/ml
phytohemagglutinin (PHA; Sodiag, Losone, Switzerland) and
1x106/ml irradiated allogeneic PBMCs (3’000 rad) as feeder
cells. A2/multimer+ T cell clones were expanded by periodic
(every 15 days) restimulation in 24-well plates with PHA,
irradiated feeder cells and hrIL-2.
Direct ex vivo cell sorting, cDNA amplification and
single cell gene-specific PCR
Single or five-cell aliquots were sorted directly ex vivo from T
cell subsets of interest and cDNA preparation and global cDNA
amplification performed as previously described [27,28]. Gene
signature of individual T cell was identified by gene-specific
PCRs as described [28] and PCR products visualized after
electrophoresis on a 2.5% agarose gel. We used the following
primers: GAPDH: 5’-GGACCTGACCTGCCGTCTAG-3’; rev-5’-
CCACCACCCTGTTGCTGTAG-3’, beta2 microglobulin: 5’-
CCAGCAGAGAATGGAAA GTC-3’; rev-5’-
GATGCTGCTTACATGTCTCG-3’, CCR7: 5’-
CCAGGCCTTATCTCC AAGACC-3’; rev-5’-
GCATGTCATCCCCACTCTG-3’, CD27: 5’-
ACGTGACAGAGTGCC TTTTCG-3’; rev-5’-
TTTGCCCGTCTTGTAGCATG-3’, IL7R (IL-7Ra/CD127): 5’-
ATC TTGGCCTGTGTGTTATGG-3’; rev-5’-
ATTCTTCTAGTTGCTGAGGAAACG-3’; EOMES
(eomesodermin): 5’-AGCAGGCTGTGAACATTGG-3’; rev-5’-
TTGACTCCTGGG CCTAGTATC-3’, CCR5: 5-
TCAGCAGGAAGCAACGAAGG-3’; rev-5’-TCTTTGACTTG
GCCCAGAGG-3’, KLRD1 (CD94): 5’-
GTGGGAGAATGGCTCTG CAC-3’; rev-5’-
TGAGCTGTTGCTTACAGATATAACGA-3’, IFNG (IFN-): 5’-
GCCAAC CTAAGCAAGATCCCA-3’; rev-5’-
GGAAGCACCAGGCATGAAATC-3’, PRF1 (Perforin): 5’-
TTCACTGCCACGGATGCCTAT-3’; rev-5’-
GCGGAATTTTAGGTGGCCA-3’, GZMB (Granzyme B): 5’-
GCAGGAAGATCGAAAGTGCGA-3’; rev-5’-GCATGCCAT
TGTTTCGTCCAT-3’, SELL (CD62L): 5’-
CCGTCTGTGAATTGGACCAT-3’; rev-5’-AAC
AGCAAAACCCCCAAACT-3’.
TCR spectratyping, sequencing and TCR clonotyping
TCR spectratyping [14] was used to identify all TCR
clonotypes, which were classified according to the
ImMunoGeneTics (IMGT) nomenclature proposed by Lefranc
and colleagues (http://imgt.org/)[29]. To rapidly identify TRBV
segment usage, cDNA pools of EBV antigen-specific CD8 T
cells were initially subjected to individual PCR using a set of
previously validated fluorescent-labeled forward primers
specific for the 22 TCR BV subfamilies and one unlabeled
reverse primer specific for the constant region of the beta chain
of the TCR [30]. This TRBV-CDR3 spectratyping analysis
represents a prescreening step that allows saving time and
reagents (data not shown). Once positive TRBV subfamilies
were identified, individual cDNA samples generated from either
ex vivo sorted single cell samples (n = 477) and 5-cell samples
(representing the equivalent of 300 to 450 EBV-specific CD8 T
cells per healthy donor or melanoma patient) or from in vitro
generated T cell clones (healthy donors, n = 530 clones;
melanoma patients, n = 779 clones) were subjected to TRBV-
specific PCRs. Separation and detection of amplified PCR
fragments that contained the entire CDR3 segment were
performed in the presence of fluorescent size markers on an
ABI PRISM 310 Genetic Analyzer (AppliedBiosystems/Life
Technologies Corporation, Zug, Switzerland) and data were
analyzed with GeneScan 3.7.1 (AppliedBiosystems). In the last
step, PCR products of interest were directly purified and
sequenced with the reverse primer (Fasteris SA, Geneva,
Switzerland). The majority of PCR products were sequenced,
however for several dominant TCR clonotypes (n = 8 for HDs;
n = 10 for patients), unique primers corresponding to the CDR3
gene segment were designed and used for clonotyping PCRs
as previously described [15]. All ex vivo single cell, 5-cell, and
in vitro generated T cell clone cDNA samples from healthy
donors and melanoma patients were processed in the same
rigorous approach.
Statistical analyses
As indicated throughout the text, Kruskal-Wallis non-
parametric, one-way ANOVA and Spearman’s correlations
were performed with Prism 5.0 (La Jolla, California, USA) and
P < 0.05 was considered as statistically significant. Co-
expression pie charts were compared with each other using
10’000 permutations calculated with the Software SPICE 5.2
(NIH, Bethesda, USA).
Results
Enhanced effector cell differentiation of EBV antigen-
specific CD8 T cells following transient lympho-
depletion and immune reconstitution
Recent immunotherapy trials have shown that lympho-
depletion induced by non-myeloablative chemotherapy favored
subsequent expansion of adoptively transferred T cells by
homeostatic mechanisms ([31]; Figure 1A). To further refine
Clonal Repertoire upon Transient Lympho-Depletion
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this strategy, we had previously analyzed the impact of three
different non-myeloablative conditioning chemotherapy
regimens on lympho-depletion and reconstitution in melanoma
patients [24,25]. The three chemotherapeutic regimens induced
significant transient depletion of lymphocytes, followed by
efficient recovery of total lymphocyte [24,25] and CD8 T cell
(Figure 1B, left panel) counts to normal levels four weeks after
adoptive cell transfer (post-ACT).
We then analyzed the CD8 T cells specific for the EBV lytic
protein BMFL1 from five patients with stage IV melanoma
before and after TLD (Figure S1) and from four healthy donors.
The overall proportion of EBV antigen-specific T cells before
Figure 1.  Direct ex vivo analysis of HLA-A*0201/BMFL1 specific CD8 T cells from healthy donors and melanoma
patients.  A. Schematic representation of non-myeloablating lympho-depleting treatment followed by ACT of PBMCs for melanoma
patients. Blood samples were analyzed for all patients at the leukapheresis time-point (Leuka) before TLD chemotherapy and post-
ACT (time-point T1), which corresponded to day 32 (patient LAU 1144), day 45 (LAU 1013), or day 60 (LAU 618, LAU 936, and LAU
672). B. Left panel; total counts of CD8 T cells from five melanoma patients at Leuka and post-ACT. Right panel; phenotype of total
CD8 T cells showing proportions of early-differentiated (EM28pos; CCR7negCD45RAnegCD28pos) and late-differentiated (comprising of
EM28neg; CCR7negCD45RAnegCD28neg and EMRA; CCR7negCD45RAposCD28neg) subsets from four healthy donors (HDs) and from five
melanoma patients at Leuka and post-ACT. C. Left panel; total counts of EBV-specific CD8 T cells in peripheral blood from five
melanoma patients at Leuka and post-ACT time points. Right panel; phenotype of EBV-specific CD8 T cells showing proportions of
early-differentiated (EM28pos; CCR7negCD45RAnegCD28pos) and late-differentiated (comprising of EM28neg;
CCR7negCD45RAnegCD28neg and EMRA; CCR7negCD45RAposCD28neg) subsets from four healthy donors and from five melanoma
patients at Leuka and post-ACT. D. EBV-specific antibody levels measured in plasma samples from five melanoma patients at
various time-points before and after lympho-depleting treatment. Day 0 on the x-axis represents the day of ACT. Results are
represented as arbitrary units on a relative index scale. Plasma level evolution is shown separately for each anti-EBV antibody (anti-
VCA IgM and IgG, anti-EBNA IgG and anti-EA IgG), and the grey bar represents the cut-off between negative and positive status for
each marker.
doi: 10.1371/journal.pone.0078686.g001
Clonal Repertoire upon Transient Lympho-Depletion
PLOS ONE | www.plosone.org 4 October 2013 | Volume 8 | Issue 10 | e78686
and after treatment remained unchanged (Figure 1C; left panel;
P = 0.625, Kruskal-Wallis). As compared to healthy individuals,
BMFL1-specific CD8 T cells from melanoma patients showed
more advanced effector cell differentiation with increased
percentages of EM28neg (defined as
CCR7negCD45RAnegCD28neg) and EMRA (defined as
CCR7negCD45RAposCD28neg) subsets already before treatment
(i.e. at the time of leukapheresis) (Figure 1C; right panel).
These subsets increased further and became dominant post-
ACT. In healthy donors, such advanced effector cell
differentiation is not typically observed within EBV-specific CD8
T cells, which resembles more closely to CMV-specific T cell
responses [14,32]. To a weaker extent, advanced effector cell
differentiation was also observed in the total CD8 T cell pool
(Figure 1B; right panel), suggesting that preceding histories of
tumor progression and received treatments, such as
chemotherapy and immunotherapy, may have affected the
CD8 T cell compartment.
Transient lympho-depletion does not result in EBV
reactivation
To examine the ability of the EBV antigen-specific CD8 T cell
response to control viral activity during situations of diminished
immune control, we determined whether non-myeloablative
chemotherapy might have resulted in EBV reactivation. Plasma
antibody levels for viral capsid antigen (VCA) IgG and IgM,
Epstein-Barr nuclear antigen (EBNA) IgG, and early antigen
(EA) IgG were measured before and after TLD and ACT
treatments (Figure 1D)[33]. EBV-specific antibodies remained
stable for several months after treatment in all patients. This is
consistent with a latent EBV infection without viral reactivation,
although the latter cannot be completely excluded. The EBV
DNA copy numbers per million PBMCs were below the level of
detection by real-time PCR reaction in blood samples before
and after TLD (data not shown).
The ex vivo EBV antigen-specific CD8 T cell repertoire
following transient lympho-depletion reveals clonotype
persistence despite frequency fluctuations
We previously developed a strategy of global cDNA
amplification at the 5-cell level suitable for the direct ex vivo
assessment of individual TCR BV-CDR3beta (TRBV) gene
segment usage [14,34]. Briefly, cDNA pools of EBV epitope-
specific CD8 T cells were initially generated and used as a
screen for recurrent TRBV families. Subsequently, the
dominance of each TRBV family was determined by testing
every single 5-cell sample, comprising the pool for the positive
TRBV families, and representing the equivalent of 300 to 450
virus-specific CD8 T cells per individual. The amplified TRBV-
CDR3-JB gene segments were ultimately sequenced or PCR-
clonotyped to identify the unique TCR signature of each T cell
clonotype, as described in Materials and Methods. Using this
approach, we initially compared the TCR clonotype repertoire
of directly ex vivo sorted 5-cell of EBV-specific T cells with that
of single T cells generated by in vitro limiting dilution cultures.
Comparable proportions of individual TCR clonotype signatures
were found when using the ex vivo sorted 5-cell and the in vitro
T cell cloning approaches (Figure S2A), in agreement with
previous studies [14,15,28]. Moreover, independently
performed ex vivo sorting experiments on single virus antigen-
specific T cells, revealed similar relative frequencies of
dominant T cell clonotypes (Figure S2B). Altogether, these
results indicate that our direct ex vivo approach allows the
high-resolution molecular characterization of the clonotype
repertoire in vivo in well-defined antigen-specific
subpopulations.
We next determined the persistence of EBV BMFL1-specific
T cell clonotypes in healthy individuals over time. The majority
of clonotypes were present at both early and late time-points
(Figure 2A). Moreover, a correlation showed a statistically
significant association between the frequencies of clonotypes
detected over a period of 4 years (Figure 2B; Rho = 0.739, P <
0.001, Spearman’s correlation). We could observe the
appearance of new clonotypes over time, however these newly
detected clonotypes were of low frequencies (
< 5%) (Figure 2B). Together, these results are in line with
those previously reported by our group [14] and others [23],
and indicate that once established in healthy adults, the clonal
composition during chronic herpes viruses infection is kept
stable for at least several years.
We further assessed the EBV antigen-specific TCR
repertoire in five melanoma patients to determine the recovery
potential of dominant T cell clonotypes following TLD and ACT
(Figure 2C). Similarly to the healthy donors, the overall TCR
repertoire persisted following TLD and ACT with the large
majority of clonotypes being detectable before and after
treatment (Figure 2C). Except for patient LAU 936, the
clonotypes that either disappeared or appeared were of low
frequency (<5%), which may be related to the sensitivity of the
technique more than the actual appearance or disappearance
of a specific clonotype. Nonetheless, we found more
pronounced fluctuations in the frequencies of the detectable
clonotypes among patients compared with healthy donors,
which was especially evident for the clonotypes with
frequencies <20% (Figure 2D). Collectively, our data show that
the clonal composition of EBV-specific CD8 T cells was
globally maintained in melanoma patients undergoing TLD and
followed by immune reconstitution, despite fluctuations in
frequencies within specific patients and for clonotypes
detectable at lower frequencies.
EBV antigen-specific clonotypes bearing public TRBV
sequences are frequently shared between healthy
donors and melanoma patients
A major similarity of EBV epitope-specific CD8 T cells
between healthy adults and patients was the preferential in vivo
selection of dominant clonotypes with TRBV chains belonging
to the TRBV14, TRBV20 and TRBV29 families (Figure 2). We
also identified at least fourteen public TRBV sequences, with
two CDR3 motifs RDxTGNGY and VGxGGTNEKL, which were
over-represented and shared within healthy individuals and
melanoma patients (Figure 3A). Public clonotypes are defined
by the presence of the same identical TRBV-CDR3-BJ
sequence found in at least two unrelated individuals. In line
with previous reports [35], several of the public TRBV
clonotypes identified in the present study were encoded by two
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or three different nucleotide sequence variations. When we
compared the frequencies of public TRBV clonotypes within the
overall EBV-specific CD8 T cell responses, a third of them
represented dominant clonotypes (with frequencies >5%)
(Figure 3B). Between 35 to 48% of EBV antigen-specific
clonotypes were found at low frequencies (between 1 and 5%),
while about one quarter were found only once in healthy
donors or patients. Together, our data showed evidence for a
high level of similarity of EBV BMFL1-specific CD8 T cells
between melanoma patients and healthy individuals, as
illustrated by (i) the sharing of frequent public TRBV sequences
and (ii) the persistence of these public TRBV clonotypes with
time and following TLD.
Figure 2.  Ex vivo TCR beta-chain clonotype composition among EBV-specific CD8 T cells over time in healthy donors and
melanoma patients.  A and C. TRBV clonotype composition of EBV-specific CD8 T cells in PBMCs from two healthy donors (A) at
early (2002) and late (2006) time-points, and in PBMCs from four melanoma patients (C) at Leuka time-point and post-ACT. Each
clonotype is represented by its specific TRBV family and its code number (clono). Clonotype frequencies are calculated by the
presence of each clonotypic sequence among individual 5-cell samples (healthy donors, n = 142; melanoma patients, n = 344)
sorted directly ex vivo. Of note, only frequencies from either new “increasing” or “declining” clonotypes are depicted. B and D.
Correlation of individual clonotype frequencies obtained from ex vivo sorted 5-cell samples (B) between blood samples at early
(2002) and late (2006) time-points from two healthy donors and (D) between Leuka and post-ACT from five melanoma patients
(Spearman’s correlation). Insets show the correlation between TCR clonotypes with frequencies below 10% for healthy donors and
20% for patients.
doi: 10.1371/journal.pone.0078686.g002
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Enhanced gene expression polyfunctionality by
individual EBV antigen-specific CD8 T cells after
transient lympho-depletion and immune reconstitution
To further investigate the effect of TLD and ACT, we
characterized the evolution of the EBV epitope-specific CD8 T
cell response in patient LAU 1013 who underwent two
successive cycles of TLD and immune reconstitution (Figure
4A), without showing signs of EBV reactivation (Figure 1D).
The frequency of EBV-specific early-differentiated “memory-
Figure 3.  In vivo selection of public TCR clonotypes in
healthy donors and melanoma patients.  A. Compilation of
the 14 public amino acid TCR beta-domain sequences
detected among three healthy individuals and five melanoma
patients. Each TCR beta-chain clonotype is described by the
TRBV segment, CDR3-beta sequence, TRBJ segment, number
of nucleotide sequence variants identified for each amino acid
sequence, as well as the proportion of healthy donors and
patients from which each sequence was identified. B.
Distribution of public sequences within the overall EBV-specific
CD8 T cells in healthy donors and patients according to their
relative frequency; dominant clonotypes (with frequency >5%)
are represented in black, low dominant (1-5%) in grey and
unique sequences in white.
doi: 10.1371/journal.pone.0078686.g003
like” EM28pos and late-differentiated EM28neg/EMRA CD8 T
cells were comparable between the two leukapheresis time-
points (Leuka I and Leuka II) (Figure 4B). In line with the data
shown in Figure 1, we observed enhanced effector cell
differentiation of the EBV-specific T cells before (at Leuka I)
and following lympho-depletion (Leuka II), when compared to
virus-specific T cells from healthy donors.
Recently, we optimized the previously described strategy of
global cDNA amplification for the direct ex vivo single cell
gene-expression profiling [13,28] and applied it here with the
aim of determining the fine changes in gene expression
signatures over the course of TLD and ACT treatment in
individual T cells. Gene-specific PCR was done for multiple
memory/homing-associated molecules (CD27, IL7R, EOMES,
CD62L/SELL and CCR5), as well as effector-related genes
known to be upregulated along T cell differentiation (PRF1,
KLRD1, IFNG and GZMB) (Figure 4C). The highest overall
expression of memory-associated genes was found at Leuka I
in the early-differentiated EM28pos virus-specific subset,
whereas the equivalent late-differentiated EMRA T cells
exhibited the greatest expression of effector-related genes.
Importantly, EM28pos virus-specific T cells at Leuka II showed
enhanced expression of effector-associated mRNA transcripts
compared to EM28pos found after Leuka I (P < 0.001, ANOVA)
(Figure 4C).
We then analyzed the level of co-expression patterns of
either memory/homing-associated or effector-associated genes
in individual EBV antigen-specific T cells from the early-
differentiated EM28pos subsets (Figure 5). T cells from Leuka I
showed the largest proportion of cells co-expressing at least
four memory-associated genes, followed by the virus-specific T
cells isolated from the Leuka II EM28pos and D15/22 subsets
(Figure 5, top pies). Interestingly, the EM28pos specific T cells
from Leuka I depicted again limited co-expression of effector
genes (Figure 5, bottom pies), contrasting with the increased
gene expression diversity observed in both memory- and
effector-associated genes following the second round of
lympho-depletion (Leuka II and D15/22). These findings further
support the notion that TLD and immune recovery induced T
cell differentiation of EBV-specific CD8 T cells, while
maintaining memory-related gene co-expression to a relative
high level.
In vivo persistent EBV antigen-specific T cell
clonotypes reveal a polyfunctional memory gene-
expression profile
By combined characterization of cell differentiation and
TRBV-CDR3 sequencing, direct ex vivo analysis of T cell
responses allows longitudinal description of individual
clonotypes [13,15,28]. With this strategy, we sought to identify
the optimal set of memory-related genes that would best
identify T cell clonotypes that survived chemotherapy and
persisted over time. High expression of memory/homing
associated mRNA transcripts was observed in the dominant
BV14c1 clonotype from patient LAU 618 (Figure 6A), which
was selected following lympho-depletion and immune
reconstitution, 74% and 80% clonotype frequency before and
after treatment, respectively (Figure 2C). We then extended our
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Figure 4.  Ex vivo gene-expression profiling of single EBV
antigen-specific CD8 T cells following cell differentiation
from patient LAU 1013.  A. Schedule of the treatment regimen
for patient LAU 1013, who received two rounds of TLD
(depicted as grey boxes). The grey arrows indicate
leukapheresis (Leuka I and Leuka II) and reinfusion of PBMCs,
respectively. Blood samples were taken at day 45 (post-Leuka
I) and at day 15/22 (post-Leuka II) after reinfusion. B.
Phenotype of EBV BMFL1-specific CD8 T cells (left panel) and
total CD8 T cells (right panel) showing the proportions of early-
differentiated (EM28pos; CCR7negCD45RAnegCD28pos) and late-
differentiated (comprising of EM28neg;
CCR7negCD45RAnegCD28neg and EMRA;
CCR7negCD45RAposCD28neg) subsets in PBMCs taken from
patient LAU 1013 at Leuka I (n = 2) and Leuka II (n = 3) time
points. Error bars (mean +/- SD) represent independent
experimental replicates. C. Direct ex vivo cumulative
expression of memory/homing-associated genes (CD62L/
SELL, CCR5, IL7R, CD27 and EOMES) and effector-related
genes (PRF1, KLRD1/CD94, IFNG and GZMB). Single EBV-
specific CD8 T cells were sorted from early-differentiated
EM28pos and late-differentiated EMRA at Leuka I (n = 266) and
Leuka II (n = 162) time-points and processed for global cDNA
amplification as described in Materials and Methods. P-values
were performed by one-way ANOVA test; ns, not significant.
doi: 10.1371/journal.pone.0078686.g004
analysis to patient LAU 1013 and performed highly sensitive
single cell gene expression analysis on four EBV-specific T cell
clonotypes selected based on their persistence following the
two rounds of TLD and ACT. From Leuka I to Leuka II,
clonotypes BV29c1 increased in frequencies (4% to 24%),
clonotype BV20c2 was stable (5% to 7%), whereas clonotypes
BV29c3 and BV20c1 decreased in frequencies (42% to 2% and
31% to 4%, respectively) (Figure 6B).
We assessed the memory/homing-associated gene
expression profiles of the four T cell clonotypes (Figure 6C) at
Leuka I time-point. The persisting BV29c1 clonotype showed
significantly enhanced expression of CD62L/SELL, IL7R and
CD27, compared to the BV29c3 and BV20c1 clonotypes, which
declined after the first round of TLD (P = 0.002 and P = 0.041
respectively; ANOVA). No major difference in the overall gene
expression of effector mediators could be detected (Figure S3).
We also analyzed the gene expression polyfunctionality by
determining the direct ex vivo co-expression patterns of
memory/homing-related genes within the co-dominant virus-
specific clonotypes in patient LAU 1013 (Figure 6D). Again, the
BV29c1 clonotype, which persisted after both lympho-depletion
regimens, revealed the highest degree of memory co-
expression genes at Leuka I (largely co-expressing four to five
memory-associated genes). Conversely, the non-persistent
BV29c3 and BV20c1 clonotypes, showing statistically
significantly reduced co-expression of mRNAs coding for
memory/homing-mediating molecules. Finally, and despite its
low clonotypic frequency, the BV20c2 clonotype maintained
robust memory/homing-related gene co-expression after the
first round of TLD (Leuka II). Of note, complete gene
expression profiling of the BV7c1 clonotype, which was
selected following several rounds of treatment (Figure 6B;
Leuka II), was not possible at Leuka I, as we were unable to
identify sufficient individual T cells for the analysis.
Collectively, these results suggest that distinct co-expression
patterns of memory-mediating molecules may be involved in
the selection and persistence of EBV antigen-specific CD8 T
cell clonotypes following transient immune-suppression.
Furthermore, this polyfunctional expression profile
characterized by high levels of co-expression of memory/
homing-related genes may represent a hallmark of T cell
clonotypes that are able to survive treatment with cytotoxic
drugs and persist over extended periods of time.
Discussion
The capacity of the EBV-specific immune response to
efficiently control viral infection is evidenced by the absence of
disease in long-term EBV-infected healthy individuals. Severe
immunosuppression following transplantation or HIV infection
can result in deficient EBV-specific immunity, which may lead
to EBV-associated pathology such as lymphoproliferative
disease. Transient lympho-depletion (TLD) induced by non-
myeloablative chemotherapy has become of high interest in the
field of cancer immunotherapy, as it strongly favors in vivo
survival and expansion of adoptively transferred cells
[31,36-38]. However, the ability of EBV-specific T cells to avoid
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resurging viral infection and spread following temporary state of
immunosuppression remains unknown.
In the present study, we examined the robustness of the
EBV-specific T cell response following TLD in comparison to
steady-state conditions over a period of four years. We found
that, similarly to the total CD8 population [25], EBV antigen-
specific T cells also recovered efficiently following TLD (Figure
1). Although the proportion of differentiated effector-like T cells
was variable among the different patients at the leukapheresis
time-point, this T cell population uniformly increased following
TLD and immune reconstitution. These results are consistent
with previous reports describing enhanced T cell differentiation
associated with immunosuppressive treatments [39,40], as well
as with our formal study showing a decline in naïve CD8 T cell
numbers following TLD and a proliferative expansion of
differentiated effector-memory T cells [25]. Furthermore, we
found no evidence of EBV viral reactivation shortly after ACT
and at later time-points (200 days, Figure 1), suggesting that
the lympho-depleting regimen was not severe or long enough
to cause EBV reactivation. From a clinical point of view, these
findings are encouraging as they provide further support for the
safety of short-term non-myeloablative chemotherapy regimens
[24,25].
Owing to a high fidelity DNA polymerase, viruses belonging
to the herpesviridae family are genetically stable [2], thereby
allowing the tracking of viral antigen-specific T cells over time.
We characterized the TCR beta-chain clonotype repertoire and
selection of BMFL1-specific T cells from EBVpos healthy donors
under steady-state conditions as well as EBVpos patients
undergoing short-term chemotherapy. We found that the T cell
clonotype selection and composition of the CD8 T cell
response to an immunodominant epitope among patients
closely resembled that of healthy individuals (Figure 3).
Specifically, both groups displayed a similar degree of
clonotype diversity, with selection for dominant T cell
clonotypes bearing preferential TRBV20 and TRBV29 gene
segments. Interestingly, we identified several public TRBV-
CDR3 sequences that dominated the T cell clonotype
repertoires of healthy donors and patients, including the
previously identified archetypal AS01 ubiquitous TCR
Figure 5.  Co-expression of memory- and effector-related genes by individual EBV antigen-specific CD8 T cells following
two rounds of TLD and immune reconstitution.  Ex vivo gene expression polyfunctionality was determined as a measure of co-
expression of the five memory/homing-associated and the four effector-associated gene transcripts in single cell samples from the
EM28pos subset at the indicated time-points (n = 332). Colors of the pie arcs depict the co-expression of individual memory or
effector genes, whereas the color in the pie depicts the number of co-expressed memory- or effector-associated genes, as
determined by SPICE 5.2. Increased polyfunctional gene co-expression (from 0 to 4 or 5) is shown as progressive grey gradients
(from white to black). P-values of the permutation test are shown. Of note, at D45 (post-Leuka I) and D15/22 (post-Leuka II), EBV
antigen-specific T cells were not sufficiently frequent to allow separation into defined subsets, thus data represent individual virus-
specific T cells sorted from the total BMFL1/tetramer-specific population.
doi: 10.1371/journal.pone.0078686.g005
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sequence (TRBV20-1/TRBJ1-2 CSARDGTGNGYTF) [41].
These findings indicate that the T cell clonal composition
generated against the BMFL1 epitope in lympho-depleted
melanoma patients showed structurally conserved TCR
features, highly similar to those found in healthy individuals.
The pattern of antigen-specific TCRs has been recently shown
to influence the potency of immune responses during SIV/HIV
infections [42-44]. In particular, the number of public clonotypes
Figure 6.  Co-expression of memory-related genes by ex vivo sorted dominant EBV antigen-specific TCR clonotypes
before and following transient lympho-depletion.  A. Cumulative gene expression analysis of the dominant BV14c1 clonotype
from patient LAU 618 at Leuka and post-Leuka (D60) time-points. Expression of memory-associated genes was determined on 5-
cell cDNA samples sorted from early-differentiated EM28pos EBV-specific CD8 T cells (n = 28). B. Quantification of co-dominant
TCR clonotypes from patient LAU 1013 at Leuka I (n = 130) and Leuka II (n = 107) time-points, within the early-differentiated
EM28pos subset, shown in frequencies (in %). C. Cumulative memory/homing gene expression profile of single cell samples for each
of the four dominant clonotypes at Leuka I time-point. Individual EBV-specific CD8 T cell clonotypes from patient LAU 1013 were
sorted from the early-differentiated EM28pos subset (n = 94). P-values were performed by one-way ANOVA test. D. Gene co-
expression polyfunctionality was determined on single cell samples representing individual TCR clonotypes from EM28pos EBV-
specific CD8 T cell subset at Leuka I (n = 94) and Leuka II (n = 83) from patient LAU 1013. Colors of the pie arcs depict the co-
expression of individual memory genes, whereas the color in the pie depicts the number of co-expressed memory-associated
genes, as determined by SPICE 5.2. Increased polyfunctional gene co-expression (from 0 to 5) is shown as progressive grey
gradients (from white to black). P-values of the permutation test are shown.
doi: 10.1371/journal.pone.0078686.g006
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correlated inversely with the viral load after SIV challenges
[42,45]. T cell populations with public clonotypes also exhibited
a greater functional avidity, which was associated with relative
HIV control [43,44], providing new insights into the immune
parameters that mediate the spontaneous control of chronic
viral infections.
Persistence of herpes virus-specific T cell clonotypes with
time has been previously documented in humans [14,21,46].
More recently, using ex vivo new generation-sequencing,
Klarenbeek and coworkers [23] reported on the stability of the
repertoire of anti-viral CD8 T cell responses to CMV and EBV
in renal transplanted recipients by demonstrating that nearly all
virus-specific clonotypes appearing during the acute phase of
infection were maintained over time. Importantly, they showed
that the hierarchy of dominance of individual clonotypes was
preserved during several years, highlighting the robustness of
virus-specific T cell responses. In the present study, we
extended on these findings by showing that the in vivo BMFL1-
specific T cell repertoire was also stable following transient
immunosuppression, with the frequent TCR clonotypes
remaining dominant despite fluctuations in frequencies of low-
dominant clonotypes (Figure 2). The small number of patients
(n = 5) may represent a limitation of the current study, which
primarily reflects the small number of patients undergoing
phase I clinical trials using lympho-depleting chemotherapy.
Nevertheless, this cohort of EBVpos carriers represents a unique
opportunity to study the EBV-specific responses during
transient immunological perturbations, in well-defined clinical
settings, and not only over time under steady-state conditions.
The persistence of the EBV antigen-specific clonal repertoire
following TLD and immune reconstitution represents an
interesting observation as more pronounced fluctuations might
have been expected. These include de novo T cell priming and
thus the emergence of novel TCR clonotypes, and/or loss of
(less frequent) clonotypes, presumably because of increased
competition for survival factors. Moreover, the immune
reconstitution period following TLD is generally associated with
a skewing of the global CD8 T cell repertoire, in part due to
early preferential expansion of antigen-primed T cells, followed
by the slow repopulation with new thymic emigrants that
eventually re-establish a high TCR repertoire diversity
(reviewed in [47]). Furthermore, a recent analysis of the TCR
repertoire following stem cell transplantation showed that the
dynamics of recovery of the TCR repertoire diversity largely
depends on the source of donor cells, with cord-blood cells
being the most efficient, whereas T cell-depleted peripheral
blood stem cells the least efficient at rapidly establishing TCR
diversity [48]. Since the source of our re-infused cells was
autologous unmodified PBMCs, we did not expect this to have
a major impact on the overall TCR diversity following ACT.
Specifically, our results did not show evidence of TCR
repertoire significant narrowing following transient lympho-
depletion and immune reconstitution since the majority of
dominant EBV-specific T cell clonotypes survived efficiently to
TLD.
Narrowing of the CD8 TCR repertoire can be observed in old
age and/or by CMV infection, leading to increased susceptibility
to infection [49]. In the present study, the CMV positive status
did not correlate with a more restricted EBV-specific TCR
repertoire (e.g. patients LAU 618, LAU 672 and LAU1013),
however the most restricted EBV-specific TCR repertoires
before treatment were observed for the two oldest patients in
our cohort (LAU 1144 and LAU 618). Nevertheless, despite the
advanced age and restricted TCR repertoires, total and EBV-
specific CD8 T lymphocyte counts recovered well following
chemotherapy and adoptive cell transfer.
Technological advancements in the characterization of T
lymphocyte responses reveal an unforeseen degree of
heterogeneity of the antigen-primed T cell pool. Moreover, the
level of polyfunctionality manifested by individual T cells can
often be under-estimated when studying defined cellular
populations by flow cytometry. In contrast, single cell analyses
allow the accurate characterization of the functional phenotype
of individual T cells. Our group and others have developed
sophisticated laboratory techniques to analyze the gene
expression signatures in individual T cells directly ex vivo
[28,50,51]. Such analyses provide significant advantages in the
context of characterizing antigen-specific immune responses.
Single cell gene expression profiling can complement flow
cytometry data by expending the number of genes/populations
markers used to define specific subpopulations, thereby
offering a more detailed characterization of memory or effector
subsets. For instance, this technique has proven useful in
identifying previously unrecognized subsets of CD8 T cells
differentially induced by various vaccines [51] as well as
revealing important differences between the polyfunctional
gene-expression profiles of T cells induced after vaccination
with two closely related tumor antigenic peptides [13,28]. In
these studies, gene expression analysis was extensively
validated by comparisons with expression at the protein level
using multi-parameter flow cytometry [13].
Direct ex vivo single T cell gene expression analyses allows
the accurate determination of the genes expressed by (multiple
representatives of) individual TCR clonotypes. As the
generation of clonotypic-specific mAbs to identify such
individual clonotypes by flow cytometry still remains technically
challenging, the identification of single T cell clonotypes is
currently most reliably performed at the gene expression level.
We have previously shown strong concordance between TCR
repertoire analysis performed on ex vivo sorted cells and in
vitro generated T cell clones [28], as well as between
independently performed ex vivo single-cell sorted experiments
(Figure S2). These data were obtained from ex vivo sorted
single cells, representing the equivalent of 300 to 450 cells per
healthy donor or melanoma patient. They indicate the high
sensitivity of our molecularly based approach for assessing
gene expression in individual antigen-specific T cell clonotypes
directly ex vivo, and allow the fine characterization of the
parameters involved in memory T cell formation and
maintenance over time (Figures 4 to 6).
ACT studies performed in mice show that T cell populations
expressing L-selectin (CD62L) and IL-7Ra display improved
survival compared with subsets lacking the expression of these
markers [52,53]. Results from clinical trials involving ACT in
humans suggest that early-differentiated central memory T
cells have a survival advantage in vivo due to their enhanced
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proliferative and self-renewal capacities after adoptive transfer
[38,54,55]. We recently reported that under steady-state
conditions, the early-differentiated EM28pos EBV-specific T cells
show high co-expression of memory/homing-related genes and
relatively infrequent effector-gene expression [28]. Thus, we
hypothesized that the persisting anti-viral CD8 T cell
clonotypes might exhibit a memory-associated phenotype,
which would favor their persistence following TLD. By profiling
the expression of genes related to memory/homing and effector
T cell properties, we found that persisting clonotypes (such as
the BV29c1 clonotype from patient LAU 1013 and BV14c1 from
patient LAU 618) showed specific and robust gene co-
expression of CD27, IL7R, and CD62L/SELL prior to treatment
(Figure 6). Conversely, we observed significant differences in
the memory gene expression profiling among two other
dominant but non-persisting T cell clonotypes (BV29c3 and
BV20c1 from patient LAU 1013). Although this in-depth
analysis was only possible on few clonotypes, our data suggest
that a polyfunctional memory/homing gene co-expression
profile before TLD may be predictive of TCR clonotypes with
improved survival during the immune reconstitution period.
These results are in line with the concept that polyfunctional
viral-specific T cells have also been observed in responses to
the persistent and well-controlled CMV viral infection [28], as
well as within long-term non-progressors of HIV-infected
individuals [56]. Identifying specific gene expression profiles
involved in the survival and persistence of antigen-specific T
lymphocytes over time will help us in understanding correlates
of immune protection and are essential to promote therapeutic
immune intervention like vaccination or adoptive T cell therapy.
CD27 expression on T cells is associated with resistance to
apoptosis, high IL-2 production, and increased T cell expansion
[57], while IL-7Ra is a hallmark of primed CD8 T cells with the
capacity to develop into long-lived memory cells [52,58]. As a
result of cytoreduction following lympho-depleting
chemotherapy, there is an increase in serum levels of IL-7 and
IL-15 due to diminished competition for these cytokines [47]. As
such, T cells expressing IL-7 and IL-15 receptors are expected
to have survival and proliferative advantages during the
immune reconstitution period. Our group previously reported
that serum levels of IL-7 were detectable in these patients
before TLD and ACT, and remained elevated for long periods
of time following treatment [25]. Here, we show that despite the
induction of T cell differentiation following TLD and immune
recovery, anti-viral persistent T cell clonotypes retained relative
high gene expression of IL7R and CD27 even after two rounds
of lympho-depletion treatment. Collectively, these data provide
further support for the crucial role of IL-7 in memory T cell
homeostasis and persistence, and the potential clinical benefits
of including IL-7 administration in future vaccination and ACT
strategies.
In conclusion, detailed analyses of phenotype, gene
expression and TCR clonal repertoire of EBV antigen-specific
CD8 T cells in healthy donors and melanoma patients revealed
that the anti-viral specific clonotypes persisted over time and
showed the ability to resist cytotoxic chemotherapy.
Importantly, the in vivo setting studied here differs from the
well-established allogeneic bone marrow transplantation in
which the immunological perturbations are likely more
profound. It also differs from the phase I clinical trials, which
involve the same non-myeloablative lympho-depleting
chemotherapy regimens, but with the transfer of either tumor-
infiltrating lymphocyte cultures [31] or autologous CD3 T
lymphocytes engineered with antigen-specific TCRs [59,60].
Future studies are needed to characterize the impact of these
in vivo settings on the dynamics of anti-viral T cell responses.
Furthermore, direct ex vivo high-resolution molecular
characterization of individual T cells at the clonotype level, as
shown here, provides enhanced insights in the processes
shaping the in vivo long-term survival of anti-viral specific T
cells.
Supporting Information
Figure S1.  Ex vivo phenotype analysis of HLA-A*0201/
BMFL1-specific CD8 T cells in melanoma patients before
and after transient lympho-depletion. Representative ex vivo
flow cytometry analysis of EBV antigen-specific CD8 T cells in
patient LAU672 at time-points before (Leuka) and after TLC
(post-ACT). Total CD8 T cells (R1 gated top panels) and EBV-
multimerpos T cells (HLA-A2/BMLF1 defined as GLC/A2; R2
gated bottom panels) were characterized for the cell surface
expression of CCR7 and CD45RA (middle panels). Double
staining for CD45RA and CD28 is shown for CCR7 negative
gated populations. Quadrant percentages are depicted for each
subset.
(TIF)
Figure S2.  Reproducibility of TCR BV clonotype analysis.
A. Positive correlation of clonotype frequencies obtained
between direct ex vivo 5-cell sample sorting (n = 162) and in
vitro generated single-cell cloning (n = 676) by Spearman’s
correlation. Plot shows all TCR clonotypes identified in blood
samples at leukapheresis time-points from four melanoma
patients with inset showing the correlation between TCR
clonotypes with frequencies below 20%. B. Analysis of the
TCR repertoire diversity of EBV-specific CD8 T cells from
patient LAU 1013 at leuka II (n = 107) obtained from single-cell
samples directly ex vivo sorted from two separate experiments.
Each dominant clonotype is indicated and color-coded. Non-
dominant clonotypes are designed as “BV others” and are
composed of non-clonotypic sequences.
(TIF)
Figure S3.  Co-expression of effector-related genes by
dominant EBV antigen-specific TCR clonotypes before and
following transient lympho-depletion. A. Cumulative
effector-gene expression profile of single cell samples for each
of the four dominant clonotypes at Leuka I time-point. Individual
EBV antigen-specific CD8 T cell clonotypes from patient LAU
1013 were sorted from the early-differentiated EM28pos subset
(n = 94). B. Gene co-expression polyfunctionality was
determined on single cell samples representing individual TCR
clonotypes from EM28pos EBV antigen-specific CD8 T cell
subset at Leuka I (n = 94) and Leuka II (n = 83) from patient
LAU 1013. Colors of the pie arcs depict the co-expression of
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individual effector genes (PRF1, KLRD1/CD94, IFNG and
GZMB), whereas the color in the pie depicts the number of co-
expressed effector-related genes, as determined by SPICE 5.2.
Increased polyfunctional gene co-expression (from 0 to 4) is
shown as progressive grey gradients (from white to black). P-
values of the permutation test are shown.
(TIF)
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